Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
Immuno-oncology is one area where Merck & Co could see a challenge from its historic parent company.